Výsledky vyhledávání - "MESH: Endpoint Determination"

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)

Publikováno v: European Journal of Cancer
European Journal of Cancer, Elsevier, 2014, 50 (17), pp.2983-2993. ⟨10.1016/j.ejca.2014.07.011⟩
European Journal of Cancer, Elsevier, 2014, 50 (17), pp.2983-2993. 〈10.1016/j.ejca.2014.07.011〉
European Journal of Cancer, 2014, 50 (17), pp.2983-2993. ⟨10.1016/j.ejca.2014.07.011⟩
European Journal of Cancer, 50(17), 2983-2993

International audience; BACKGROUND:Using potential surrogate end-points for overall survival (OS) such as Disease-Free- (DFS) or Progression-Free Survival (PFS) is increasingly common in randomised controlled trials (RCTs). However, end-points are to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0107770bc5e54216c1633117525092a
https://doi.org/10.1016/j.ejca.2014.07.011

Zobrazit plný text záznamu

Predictive value of autoantibodies from anti-CCP2, anti-MCV and anti-human citrullinated fibrinogen tests, in early rheumatoid arthritis patients with rapid radiographic progression at 1 year: results from the ESPOIR cohort

Autor: Degboé, Yannick, Constantin, Arnaud, Nigon, Delphine, Tobon, Gabriel, Cornillet, Martin, Schaeverbeke, Thierry, Chiocchia, Gilles, Nicaise-Roland, Pascale, Nogueira, Leonor, Serre, Guy, Cantagrel, Alain, Ruyssen-Witrand, Adeline, Saraux, Alain

Publikováno v: RMD Open : Rheumatic & Musculoskeletal Diseases
RMD Open : Rheumatic & Musculoskeletal Diseases, 2015, 1, 8 p. ⟨10.1136/rmdopen-2015-000180⟩
RMD Open
RMD Open : Rheumatic & Musculoskeletal Diseases, EULAR ; BMJ, 2015, 1, 8 p. ⟨10.1136/rmdopen-2015-000180⟩
RMD Open : Rheumatic & Musculoskeletal Diseases, EULAR ; BMJ, 2015, 1 (1), pp.e000180

Objectives: We compared the ability of antibodies against cyclic citrullinated peptides (anti-CCP2), against mutated citrullinated vimentin (anti-MCV) and against citrullinated fibrinogen (AhFibA) to predict 1 year rapid radiographic progression (RRP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fa6791062e0f00fc63a5478b2558105
https://ut3-toulouseinp.hal.science/hal-03256094

Zobrazit plný text záznamu

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists

Autor: Nicolas Methy, Franck Bonnetain, Laurent Bedenne

Publikováno v: BMC Cancer, Vol 10, Iss 1, p 277 (2010)
BMC Cancer
BMC Cancer, BioMed Central, 2010, 10 (1), pp.277. ⟨10.1186/1471-2407-10-277⟩
BMC Cancer, BioMed Central, 2010, 10 (1), pp.277. 〈10.1186/1471-2407-10-277〉

Background Overall survival (OS) is the gold standard for the demonstration of a clinical benefit in cancer trials. Replacement of OS by a surrogate endpoint allows to reduce trial duration. To date, few surrogate endpoints have been validated in dig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b2856e5e545bb97f280e1600e041e31
http://www.biomedcentral.com/1471-2407/10/277

Zobrazit plný text záznamu

Triangular test applied to the clinical trial of azithromycin against relapses in Plasmodium vivax infections

Autor: Stéphane Ranque, Badiaga, S., Delmont, J., Brouqui, P.

Publikováno v: Malaria Journal, Vol 1, Iss 1, p 13 (2002)
Scopus-Elsevier
Malaria Journal
Malaria Journal, 2002, 1, pp.13
Malaria Journal, BioMed Central, 2002, 1, pp.13

Background Sequential analysis enables repeated statistical analyses to be performed throughout a trial recruitment period, while maintaining a pre-specified power and type I error. Thus the trial can be stopped as soon as the information accumulated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::bd7504bdda2736bcc5d88a5e238c7aaf
http://www.malariajournal.com/content/1/1/13

Zobrazit plný text záznamu

Greater Response to Placebo in Children Than in Adults: A Systematic Review and Meta-Analysis in Drug-Resistant Partial Epilepsy

Autor: Philippe Ryvlin, Alexis Arzimanoglou, Michel Cucherat, Sylvain Rheims

Publikováno v: PLoS Medicine
PLoS Medicine, Public Library of Science, 2008, 5 (8), pp.e166. ⟨10.1371/journal.pmed.0050166⟩
PLoS Medicine, Vol 5, Iss 8, p e166 (2008)

International audience; BACKGROUND: Despite guidelines establishing the need to perform comprehensive paediatric drug development programs, pivotal trials in children with epilepsy have been completed mostly in Phase IV as a postapproval replication

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81503a5cb4bdc19e051a43ce2ced13e0
https://doi.org/10.1371/journal.pmed.0050166

Zobrazit plný text záznamu

Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance

Autor: Renaud Verdon, Véronique Massari, Jean-Jacques Parienti

Publikováno v: BMC Medical Research Methodology
BMC Medical Research Methodology, 2006, 6, pp.46. ⟨10.1186/1471-2288-6-46⟩
BMC Medical Research Methodology, BioMed Central, 2006, 6, pp.46. ⟨10.1186/1471-2288-6-46⟩
BMC Medical Research Methodology, Vol 6, Iss 1, p 46 (2006)

Background The interpretation of the results of active-control trials regarding the efficacy and safety of a new drug is important for drug registration and following clinical use. It has been suggested that non-inferiority and equivalence studies ar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4360a3af3077a2854f54c7a7915bdd44
http://europepmc.org/articles/PMC1592102

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání